[18F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction. BJS 2018; 105: 419-428.
Published: 8th February 2018
Authors: T. Harustiak, M. Zemanova, P. Fencl, L. Hornofova, A. Pazdro, M. Snajdauf et al.
The aim of this prospective study was to assess whether [18F]fluorodeoxyglucose PET can be used to predict histopathological response early in the course of neoadjuvant chemotherapy in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.
Following the PET response criteria in solid tumours (PERCIST 1.0) as a standardized method for semiquantitative assessment of metabolic response, FDG‐PET/CT was performed before (PET1) and after (PET2) initiation of the first cycle of chemotherapy. The relative changes in the peak standardized uptake value (ΔSUL) and total lesion glycolysis (ΔTLG) between PET1 and PET2 were correlated with histopathological response, defined as less than 50 per cent viable tumour cells in the resection specimen. A receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut‐off value with the highest accuracy of histopathological response prediction.
PET2 was performed a median of 16 (range 12–22) days after the start of chemotherapy. Some 27 of 90 patients who underwent surgery had a histopathological response. There was no association between the median ΔSUL or median ΔTLG and the histopathological response. A
FDG‐PET/CT after the first cycle of chemotherapy does not predict histopathological response in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.Full text
You may also be interested in
Authors: M. A. Amer, M. D. Smith, C. H. Khoo, G. P. Herbison, J. L. McCall
Meta‐analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma.
Authors: N. T. E. Bird, A. McKenna, J. Dodd, G. Poston, R. Jones, H. Malik et al.
Notes: Tumour biology is important
Randomized clinical trial
Multicentre factorial randomized clinical trial of perioperative immunonutrition versus standard nutrition for patients undergoing surgical resection of oesophageal cancer.
Authors: L. A. Mudge, D. I. Watson, B. M. Smithers, E. A. Isenring, L. Smith, G. G. Jamieson et al.
Notes: No difference
Detection of carcinoembryonic antigen in peritoneal fluid of patients undergoing laparoscopic distal gastrectomy with complete mesogastric excision.
Authors: D. Xie, Y. Wang, J. Shen, J. Hu, P. Yin, J. Gong et al.
Notes: Careful surgery, fewer free cancer cells
Authors: B. J. Noordman, E. W. de Bekker‐Grob, P. P. L. O. Coene, E. van der Harst, S. M. Lagarde, J. Shapiro et al.
Notes: Organ preservation preferred
Authors: M. T. Adil, V. Jain, F. Rashid, O. Al‐taan, D. Whitelaw, P. Jambulingam et al.
Notes: Bariatric surgery improves physical function
Authors: B.‐H. Min, M. Hong, J. H. Lee, P.‐L. Rhee, T. S. Sohn, S. Kim et al.
Nomogram to predict lymph node metastasis in patients with early oesophageal squamous cell carcinoma.
Authors: H. Zheng, H. Tang, H. Wang, Y. Fang, Y. Shen, M. Feng et al.
Notes: Selecting patients for surgery or endoscopic treatment
Predictive value of abdominal CT in evaluating internal herniation after bariatric laparoscopic Roux‐en‐Y gastric bypass.
Authors: J. C. Ederveen, M. M. G. van Berckel, S. W. Nienhuijs, R. J. P. Weber, J. Nederend
Notes: Important tool for correct diagnosis
Authors: M. Kanda, D. Shimizu, H. Tanaka, C. Tanaka, D. Kobayashi, M. Hayashi et al.
Notes: Potential target for therapy
Development and validation of a difficulty score to predict intraoperative complications during laparoscopic liver resection. BJS 2018; 105: 1182-1191.
Authors: M. C. Halls, G. Berardi, F. Cipriani, L. Barkhatov, P. Lainas, S. Harris et al.
Notes: Helps improve selection for laparoscopic liver resection